Christophe Weber, president and CEO of Takeda, enthusiastically announced the development and approval of a dengue vaccine by ANMAT, marking an important milestone in the fight against this epidemiological threat in Argentina.
After more than a decade of dedication to innovation, the Japanese biopharmaceutical company, founded in 1781, celebrates this significant achievement in its commitment to ethical values centered on the patient.
Weber shared with Forbes some of the keys to Takeda's innovations and guidelines, highlighting the focus on "Value-Based Medicine".
This concept is based on shifting the attention of health systems from intervention-centered models toward tangible results for patients.
Weber emphasized the importance of measuring patient "outcomes" to achieve efficiency and cost-benefit balance, highlighting the relevance of prevention in this equation.
In the field of new drugs, Weber advocated for abandoning the "fee-for-service" model and adopting value-based approaches, focused on improving quality of life and measuring tangible results for patients.
He highlighted how this paradigm shift could be applied through an approach centered on patient "outcomes" rather than simply providing treatments.
The interview also addressed the crucial role of vaccines in this new model, with Weber sharing details about the dengue vaccine developed by Takeda.
He highlighted that the vaccine, approved by ANMAT and available in Brazil, represents a significant investment by the company and is designed to be effective and safe.
The vaccine covers all four serotypes of the virus and offers protection to people previously infected or not, being administered in two doses with a three-month interval.
Weber emphasized the importance of working in collaboration with each country to achieve the best results, and highlighted the promising results of the TIDES clinical trial, which demonstrated a significant reduction in hospitalizations and the risk of symptomatic dengue.
Weber concluded by expressing the expectation of growth alongside new generations, who value Takeda's mission of providing better health to people and a brighter future for the planet in the era of data integration, technology and artificial intelligence in biotechnology companies.
With information from: Forbes Argentina.
Receive all industry news in our weekly Newsletter Scientific Dialectics.